Tumor Biology

, Volume 37, Issue 6, pp 7481–7491 | Cite as

Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52

Original Article


The tumor protein D52 (TPD52) is an oncogene overexpressed in breast cancer. Although the oncogenic effects of TPD52 are well recognized, how its expression and the role in migration/invasion is still not clear. This study tried to explore the regulative role of microRNA-34a (miR-34a), a tumor suppressive miRNA, on TPD52 expression in breast cancer. The expression of miR-34a was found significantly decreased in breast cancer specimens with lymph node metastases and breast cancer cell lines. The clinicopathological characteristics analyzed showed that lower expression levels of miR-34a were associated with advanced clinical stages. Moreover, TPD52 was demonstrated as one of miR-34a direct targets in human breast cancer cells. miR-34a was further found significantly repress epithelial-mesenchymal transition (EMT) and inhibit breast cancer cell migration and invasion via TPD52. These findings indicate that miR-34a inhibits breast cancer progression and metastasis through targeting TPD52. Consequently, our data strongly suggested that oncogenic TPD52 pathway regulated by miR-34a might be useful to reveal new therapeutic targets for breast cancer.


Human breast cancer miR-34a TPD52 Epithelial-mesenchymal transition 



3′-Untranslated region


Dulbelcco’s modified Eagle’s media


Epithelial-mesenchymal transition


Fetal bovine serum




Institutional Review Board


Keratin 19




Phosphate-buffered saline


Quantitative real-time reverse transcription-PCR


Transforming growth factor-beta


Tumor protein D52



This study was supported by the Foundation of Educational Committee of Heilongjiang Province of China (Grant No. 12541311).

Compliance with ethical standards

The authors declare that all the patients, involved in this study, signed informed consent forms according to our institutional guidelines, and the study was approved by Institutional Review Board (IRB) protocols of Harbin Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflicts of interest


Supplementary material

13277_2015_4623_Fig6_ESM.gif (71 kb)
Supplementary Figure 1

Quantitive analysis for western blot results of TPD52 expression treated with miR-34a mimic or inhibitor in MDA-MB-231 and MCF-7 cells. Western blot analysis of TPD52 expression treated with miR-34a mimic or inhibitor was performed triplicate in MDA-MB-231 and MCF-7 cells. β-actin was used as an internal control. The band density was determined using the ImageJ software for quantitative analysis (*P<0.05 compared with control group). (GIF 71 kb)

13277_2015_4623_MOESM1_ESM.tif (815 kb)
High Resolution (TIF 815 kb)
13277_2015_4623_MOESM2_ESM.doc (46 kb)
Supplementary Table 1 (DOC 46 kb)
13277_2015_4623_MOESM3_ESM.doc (39 kb)
Supplementary Table 2 (DOC 39 kb)


  1. 1.
    Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015.Google Scholar
  2. 2.
    Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Leo AD. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015.Google Scholar
  3. 3.
    Takahashi RU, Miyazaki H, Ochiya T. The roles of microRNAs in breast cancer. Cancers (Basel). 2015;7:598–616.CrossRefGoogle Scholar
  4. 4.
    Byrne JA, Frost S, Chen Y, Bright RK. Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol. 2014;35:7369–82.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen Y, Kamili A, Hardy JR, Groblewski GE, Khanna KK, Byrne JA. Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle. 2013;12:3083–97.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tennstedt P, Bolch C, Strobel G, Minner S, Burkhardt L, Grob T. Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. Int J Oncol. 2014;44:609–15.PubMedGoogle Scholar
  7. 7.
    Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, et al. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res. 2004;64:1589–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, et al. Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res. 2008;14:5050–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, et al. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014;588:1973–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT, Kumar AP. MicroRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2015.Google Scholar
  13. 13.
    Ma W, Xiao GG, Mao J, Lu Y, Song B, Wang L, et al. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget. 2015;6:10432–44.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Agarwal S, Hanna J. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. 2015;112:61–68.Google Scholar
  15. 15.
    Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013;32:4294–303.CrossRefPubMedGoogle Scholar
  16. 16.
    Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124:1853–67.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li G, Thomas AM, Hart SN, Zhong X, Wu D, Guo GL. Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. Mol Endocrinol. 2010;24:1404–12.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Li G, Thomas AM, Williams JA, Kong B, Liu J, Inaba Y, et al. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7:e35895.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010;31:1037–44.CrossRefPubMedGoogle Scholar
  20. 20.
    Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, et al. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res. 2007;5:133–44.CrossRefPubMedGoogle Scholar
  21. 21.
    Massague J. Tgfbeta in cancer. Cell. 2008;134:215–30.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Luwor RB, Hakmana D, Iaria J, Nheu TV, Simpson RJ, Zhu HJ. Single live cell TGF-beta signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF-beta-Smad3 activity. Mol Cancer. 2015;14:50.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kumar KJ, Vani MG, Chueh PJ, Mau JL, Wang SY. Antrodin C inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via suppression of Smad2/3 and beta-catenin signaling pathways. PLoS One. 2015;10:e0117111.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013;329:125–36.CrossRefPubMedGoogle Scholar
  25. 25.
    Kasinski AL, Slack FJ. MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012;72:5576–87.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cao W, Fan R, Wang L, Cheng S, Li H, Jiang J, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 2013;34:963–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Pang RT, Leung CO, Lee CL, Lam KK, Ye TM, Chiu PC, et al. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1. BMC Cancer. 2013;13:25.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res. 2011;10:479–87.CrossRefPubMedGoogle Scholar
  29. 29.
    Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, Kulshreshtha R. HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFbeta-signaling in hypoxic microenvironment. Sci Rep. 2015;5:9650.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ren Y, Zhou X, Yang JJ, Liu X, Zhao XH, Wang QX, et al. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett. 2015;362:174–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Li W, Zhai L, Zhao C, Lv S. MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer. Breast Cancer Res Treat. 2015;150:501–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Su CM, Lee WH, Wu AT, Lin YK, Wang LS, Wu CH, et al. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J Nutr Biochem. 2015;26:675–85.CrossRefPubMedGoogle Scholar
  33. 33.
    Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, et al. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci. 2015;106:700–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H: Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 2011;10:M111 010462.Google Scholar
  35. 35.
    Hahn S, Jackstadt R, Siemens H, Hunten S, Hermeking H. Snail and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J. 2013;32:3079–95.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014;53:807–19.Google Scholar
  37. 37.
    Kabir NN, Ronnstrand L, Kazi JU. Keratin 19 expression correlates with poor prognosis in breast cancer. Mol Biol Rep. 2014;41:7729–35.CrossRefPubMedGoogle Scholar
  38. 38.
    Xiao X, Chen B, Liu X, Liu P, Zheng G, Ye F, et al. Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One. 2014;9:e112720.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Katoh K, Nakanishi Y, Akimoto S, Yoshimura K, Takagi M, Sakamoto M, et al. Correlation between laminin-5 gamma2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue. Oncology. 2002;62:318–26.CrossRefPubMedGoogle Scholar
  40. 40.
    Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, et al. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFbeta receptor degradation in breast cancer. Carcinogenesis. 2013;34:874–84.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Guodong Li
    • 1
    • 2
  • Lei Yao
    • 3
  • Jinning Zhang
    • 1
    • 2
  • Xinglong Li
    • 1
    • 2
  • Shuwei Dang
    • 1
    • 2
  • Kai Zeng
    • 1
    • 2
  • Yuhui Zhou
    • 1
    • 2
  • Feng Gao
    • 3
  1. 1.Department of General Surgerythe Fourth Affiliated Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Bio-Bank of Department of General Surgerythe Fourth Affiliated Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of General Surgerythe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations